PATENT
Attorney Docket No. 232046
Client Reference No. E-191-2002/0-US-03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Boyd et al.

U.S. National Phase of PCT/US2003/023290

Group Art Unit: Unassigned

Examiner: Unassigned

Filed: Herewith

For: CHONDROPSIN-CLASS ANTITUMOR

V-ATPase INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF

USE THEREOF

INFORMATION DISCLOSURE STATEMENT

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.


The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner place his or her initials in the appropriate area on the enclosed Form 1449, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form 1449 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.


The Information Disclosure Statement is being filed:

within any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as



set forth in 37 CFR 1.491 of an international application; (c) before the mailing date of a first Office Action on the merits; or (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114. after (a), (b), (c) or (d) above, but before the mailing date of a final action under П 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and includes *one* of: the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below). orthe fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below). after the mailing date of a final action under 37 CFR 1.113 or a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and on or before payment of the issue fee, and includes the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below). after the mailing date of a Notice of Allowance under 37 CFR 1.311, and on or before \Box payment of the issue fee, and within thirty days of receiving each item of information contained in the Information Disclosure Statement, and includes the Statement under 37 CFR 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below). NOTE: This is for original applications except applications for a design patent, filed on or after May 29, 2000, wherein a paper containing only an Information Disclosure Statement in compliance with 37 CFR 1.97 and 1.98 is being filed. Copies of the References Copies of all of the references listed on the enclosed Form 1449 are enclosed herewith. Copies of references identified on the accompanying Form 1449 are enclosed \boxtimes herewith. Attached to each reference not in the English language is a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3). An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3). \boxtimes A copy of the foreign search report is enclosed herewith. The references listed on the enclosed Form 1449 were previously identified in the parent application(s) of the present application, and copies of the references were

furnished at that time. Accordingly, additional copies of the references are not submitted herewith, so as not to burden the file with duplicate copies of references.





The Examiner is respectfully requested to carefully review the references in accordance with the requirements set out in the Manual of Patent Examining Procedure. In accordance with 37 CFR 1.98(d), the details of the parent application(s) relied upon for an earlier filing date under 35 USC 120 in which copies of the references were previously furnished are set out below:

	U.S. APPLI	CATIONS	Status (check one)						
U.	S. APPLICATIONS	U.S. FILING DATE	PATENTED	PENDING	ABANDONED				
1.									
2.									
3.									
State	ment under 37 CFR	1.97(e)							
	The undersigned hereby states that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.								
	The undersigned hereby states that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.								
Stater	nent under 37 CFR	1.704(d)							
	The undersigned hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.								
Fees									
	No fee is owed by the IDS Fee of \$18	he applicant(s). 30 under 37 CFR 1.17(p)	is enclosed he	erewith.					
Method of Payment of Fees									

Charge Deposit Account No. 12-1216 in the amount of \$. . . (A duplicate copy of

Attached is a check in the amount of \$

this communication is enclosed for that purpose.)

In re Appln. of Boyd et al. Attorney Docket No. 232046 O / 521930
DT01 Rec'd PCT/PTE 2 4 JAN 2005

Authorization to Charge Additional Fees


If any additional fees are owed in connection with this communication, please charge Deposit Account No. 12-1216. (A duplicate copy of this communication is enclosed for that purpose.)

Instructions as to Overpayment

Credit Account No. 12-1216.
Refund

Xavier Pillai, Reg. No. 39,799 LEYDIG, VOIT & MAYER, LTD. Two Prudential Plaza, Suite 4900 180 North Stetson Avenue Chicago, Illinois 60601-6780 (312) 616-5600 (telephone) (312) 616-5700 (facsimile)

Date: January 24, 2005





1

DT01 Rec'd PTC	2	4	JAN	2005
----------------	---	---	-----	------

Substitute	for	form	1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary) Sheet

Complete if Known							
Application Number	Unassigned AU JCLIJU						
Filing Date	Herewith						
First Named Inventor	BOYD et al.						
Group Art Unit	Unassigned						
Examiner Name	Unassigned						
Attorney Docket Number	232046						

	U.S. PATENT DOCUMENTS								
		U.S. Patent Document							
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate			
			<u> </u>			-			
		···	1						

		Foreign Patent Document					Translation	
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No*+
	AA	wo	00/51589	A2	United States of America, represented by the Secretary, Department of Health and Human Services	Sep. 8, 2000		
	ΑВ	WO	02/08231	A2	United States of America, represented by the Secretary, Department of Health and Human Services	Jan. 31, 2002		

		OTHER - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Doc. No.	I (hook magazina journal cerial eumnocium catalog etc.) date nage(c) volume iccue number (c) nublicher. I		No*+
	AC	BOWMAN et al., "Bafilomycins: A class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells," PNAS, 85, 7972-7976 (1988)		
	ΑD	CANTRELL et al., "Chondropsins A and B: Novel Tumor Cell Growth-Inhibitory Macrolide Lactams from the Marine Sponge Chondropsis sp," <i>J. Am. Chem. Soc.</i> , 122, 8825-8829 (2000)		
	ΑE	DRÖSE et al., "BAFILOMYCINS AND CONCANAMYCINS AS INHIBITORS OF V-ATPases," J. Exp. Biol., 200, 1-8 (1997)		
	ΑF	DRÖSE et al., "Inhibitory Effect of Modified Bafilomycins and Concanamycins on P- and V-Type Adenosinetriphosphatases," <i>Biochemistry</i> , <i>32</i> , 3902-3906 (1993)		
	AG	RASHID et al., "Chondropsin D, a New 37-Membered-Ring Macrolide Lactam from the Marine Sponge Chondropsis Species," <i>J. Nat. Prod.</i> , 64, 1341-1344 (2001)		
	АН	RASHID et al., "Application of High-Field NMR and Cryogenic Probe Technologies in the Structural Elucidation of Poecillastrin A, a New Antitumor Macrolide Lactam from the Sponge Poecillastra Species," Organic Lett., 4(19), 3293-3296 (2002)		
	ΑI	RASHID et al., "New chondropsin macrolide lactams from marine sponges in the genus Ircinia," <i>Tetrahedron Lett.</i> , <i>42</i> , 1623-1626 (2001)		
			_	

Examiner Signature	Date Considered	

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).